Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:1.17.1.4 (
xanthine dehydrogenase
)
1,236
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Mitomycin C (MMC), an alkylating anti-tumor agent, was activated by non-enzymatic and enzymatic mechanisms leading to DNA binding and adduct formation. However, it was enzymatically, not non-enzymatically, activated MMC which induced inter-strand DNA cross-linking, a major determinant of cell death. The enzymatic activation of MMC was catalyzed by microsomal NADPH:cytochrome P450 reductase (
P450
reductase) and cytosolic enzyme activities. Human
P450
reductase, transiently expressed from its cDNA in the COSI cells, metabolically activated MMC to generate 9 specific MMC-DNA adducts and induced inter-strand DNA cross-linking. Co-chromatography of the MMC-DNA adducts generated by
P450
reductase and sodium borohydride in separate experiments indicated that MMC was metabolized by
P450
reductase to produce 2,7-diaminomitosenes that exhibited binding to deoxyguanosine. Several experiments indicated that cytosolic enzymes which catalyzed reductive activation of MMC and DNA cross-linking included NAD(P)H:quinone oxidoreductaseI (NQOI or DT diaphorase) when present in extremely high concentrations and a unique cytosolic activity. The unique cytosolic activity was present in several mammalian cells and mouse colon and liver but absent in mouse kidney. The unique activity had properties of a diaphorase but was distinct from NQOI because of a lack of correlation between NQOI (2,6-dichlorophenolindophenol reduction) activity and the amount of MMC-reductive activation leading to DNA cross-linking. This activity was also distinct from
xanthine oxidoreductase
and NADH-cytochrome b5 reductase, 2 other enzymes that catalyze metabolic activation of MMC, because the unique activity was not inhibited by allopurinol (an inhibitor of
xanthine oxidoreductase
) and its activity was the same with NADH and NADPH (cytochrome b5 reductase is specific to NADH).
...
PMID:Non-enzymatic and enzymatic activation of mitomycin C: identification of a unique cytosolic activity. 856 27
Most acetaldehyde is generated in the liver by alcohol dehydrogenase (ADH) during ethanol metabolism. Polymorphic variants of these genes encode enzymes with altered kinetic properties, and pathophysiological effects of these variants may be mediated by accumulation of acetaldehyde. Two additional pathways of acetaldehyde generation are by the cytochrome P450 2E1 (CYP2E1) and catalase. While the amount of ethanol oxidized by these enzymes comprises a small fraction of total body ethanol clearance, the local formation of acetaldehyde by these enzymes may have important effects. Additional sources of acetaldehyde include other minor enzymes (nitric oxide synthase, other cytochrome P450s,
P450
reductase,
xanthine oxidoreductase
) as well as non-enzymatic pathways (formation of hydroxyethyl radicals from the reaction of ethanol with hydroxyl radical, and its subsequent decomposition to acetaldehyde). Acetaldehyde may have effects locally (in the cells generating it), or when delivered to other cells by the blood stream or saliva, or by diffusion from the lumen of the gastrointestinal tract. The ultimate determinants of acetaldehyde toxicity include rates of its formation, rates of oxidation, and the capacity of cellular systems to prevent or repair chemical effects of acetaldehyde (e.g. formation of protein adducts or modification of nucleic acid bases).
...
PMID:Acetaldehyde generating enzyme systems: roles of alcohol dehydrogenase, CYP2E1 and catalase, and speculations on the role of other enzymes and processes. 1759 Sep 84